Comments

Protalix BioTherapeutics Stock Price, Quotes and Forecasts

Q: What sector and industry does Protalix BioTherapeutics (PLX) operate in?

Protalix BioTherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.

PLXAMEX

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$1.57

-0.01-0.63%

At close: -

$1.57

0.000.00%

After Hours: 4:00 PM EDT

Protalix BioTherapeutics (PLX) Forecast

News Earnings Protalix BioTherapeutics (PLX) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Protalix BioTherapeutics Stock Price, Quotes and Forecasts | AMEX:PLX | Benzinga

Explore Protalix BioTherapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for PLX.

Open	$1.58
Close	$1.57
Volume / Avg.	479.61K / 951.21K
Day Range	$1.57 - $1.65
52 Wk Range	0.82 - 3.10
Market Cap	$124.98M
P/E Ratio	31.40
Dividend Yield	-
Exchange	AMEX
RSI	36
Short Interest	1.25%
Days to Cover	1.16

Recent News

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.

Vandana Singh

Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying

The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Lisa Levin

Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics

The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$1.58
Close	$1.57
Volume / Avg.	479.61K / 951.21K
Day Range	$1.57 - $1.65
52 Wk Range	0.82 - 3.10
Market Cap	$124.98M
P/E Ratio	31.40
Dividend Yield	-
Exchange	AMEX
RSI	36
Short Interest	1.25%
Days to Cover	1.16

About Protalix BioTherapeutics Inc.

Sector

Health Care

Industry

Biotechnology

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercia...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Protalix BioTherapeutics (PLX) stock?

You can purchase shares of Protalix BioTherapeutics (AMEX:PLX) through any online brokerage.

View our list of the best stock brokerages

Who are Protalix BioTherapeutics (PLX) competitors?

Other companies in Protalix BioTherapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Macrogenics (NASDAQ:MGNX), Cabaletta Bio (NASDAQ:CABA), Anixa Biosciences (NASDAQ:ANIX) and Zentalis Pharma (NASDAQ:ZNTL).

What is the forecast, or price target, for Protalix BioTherapeutics (PLX) stock?

Protalix BioTherapeutics has a consensus price target of $15.00.

What is the current price for Protalix BioTherapeutics (PLX)?

The stock price for Protalix BioTherapeutics (AMEX: PLX) is $1.57 last updated June 11, 2025 at 4:00 PM EDT.

Does Protalix BioTherapeutics (PLX) pay a dividend?

There are no upcoming dividends for Protalix BioTherapeutics.

When is Protalix BioTherapeutics (AMEX:PLX) reporting earnings?

Protalix BioTherapeutics’s Q2 earnings are confirmed for Wednesday, August 13, 2025.

Is Protalix BioTherapeutics (PLX) going to split?

There is no upcoming split for Protalix BioTherapeutics.

What sector and industry does Protalix BioTherapeutics (PLX) operate in?

Protalix BioTherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.